Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis
NCT00111449Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2003
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of etanercept in plaque psoriasis, sponsored by Amgen. Started Jun 2003; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00111449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111449.